Ticker brief
CYTK CYTOKINETICS INC
Consumer, Non-cyclical · Biotechnology
last close
$72.09
1 day
-7.5%
14 days
-2.8%
mkt cap
$11.7B
signals 14d
14
authors 14d
8
crowd 14d
+1.0σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 45% cheap · 5 pctile own 1y | IV/HV 1.26× |
| Skew — 25Δ RR 30d | +0.005 58 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +3.97 elevated | 5-session Δ +0.07 (as of 2026-07-09) |
| OI alarm | quiet | last alarm 2026-05-06 (z=2.8) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-18 → 2026-08-28 · now +0.59 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @semodough | C | -3.01 | 7 | +0.29 |
| @AponiaAnalytics | B | +4.91 | 1 | +0.25 |
| @BiopharmIQ | B | · | 1 | +0.00 |
| @MrMojoRisinX | A | -0.23 | 1 | -0.70 |
| @PersimmonTI | A | -0.57 | 1 | +0.65 |
| @fwpharma | B | +0.98 | 1 | +0.30 |
| @adamfeuerstein | A | +1.41 | 1 | +0.50 |
| @Pharmdca | C | +0.82 | 1 | +0.70 |
Recent signals14of 14 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-28 | @Pharmdca | +0.70 | Added CYTK shares above $72. — Explicitly reports adding CYTK shares around $72 or higher. | — | tweet ↗ |
| 2026-08-28 | @adamfeuerstein | +0.50 | Cytokinetics reported a successful trial that could support its next regulatory approval. | — | tweet ↗ |
| 2026-08-28 | @fwpharma | +0.30 | Reports Cytokinetics is preparing an FDA filing for non-obstructive HCM. | — | tweet ↗ |
| 2026-08-28 | @PersimmonTI | +0.65 | Reports sustained 72-week KCCQ benefit for aficamten that reversed after washout. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.70 | Reports successful Phase 3 ACACIA-HCM endpoints and a planned Q4 supplemental FDA submission. | — | tweet ↗ |
| 2026-08-28 | @semodough | +0.70 | Reports positive ACACIA-HCM results presented at ESC 2026 and published in NEJM. | — | tweet ↗ |
| 2026-08-27 | @MrMojoRisinX | -0.70 | Criticizes CYTK management for rejecting buyers and activists while insiders sold shares. | -7.5% | tweet ↗ |
| 2026-08-26 | @semodough | +0.45 | Floats a $100 year-end price outcome based on upcoming catalysts, though phrased as a question. | -9.0% | tweet ↗ |
| 2026-08-23 | @semodough | +0.00 | Flags four biotech names for a busy upcoming ESC26 week without stating a directional view. | -6.2% | tweet ↗ |
| 2026-08-21 | @BiopharmIQ | +0.00 | Reports MRNA's 177% move on positive Phase 3 endpoints and lists upcoming biotech catalysts. | -6.2% | tweet ↗ |
| 2026-08-21 | @semodough | -0.20 | Says fuller aficamten data may support efficacy but could struggle to overcome safety, cost and monitoring concerns. | -6.2% | tweet ↗ |
| 2026-08-21 | @semodough | +0.00 | BofA maintains Buy and a $104 target on BBIO after KOL discussions ahead of ESC. | -6.2% | tweet ↗ |
| 2026-08-18 | @AponiaAnalytics | +0.25 | Views continued hiring as evidence of CYTK's broader commercial buildout. | -5.3% | tweet ↗ |
| 2026-08-18 | @semodough | +0.40 | Mizuho maintains Outperform and a $118 target on CYTK ahead of launch and regulatory catalysts. | -5.3% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.